3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Expanded_access
1
Sponsor
Cancer Type
Thoracic
2
Conditions
Lung Diseases
2
Carcinoma, Non-Small-Cell Lung
2
Lung Neoplasms
1
Carcinoma
1
Interventions
Specimen Handling
613
pembrolizumab
583
Magnetic Resonance Spectroscopy
543
Carboplatin
430
Cyclophosphamide
380
Cisplatin
377
Biopsy
366
Paclitaxel
314
Nivolumab
312
Gemcitabine
308
Radiotherapy
268
Bevacizumab
230
Dexamethasone
217
fludarabine
205
Docetaxel
190
durvalumab
188
venetoclax
187
Oxaliplatin
187
Rituximab
174
Fluorouracil
174
atezolizumab
169
Pemetrexed
166
Capecitabine
162
Radiosurgery
160
Doxorubicin
160
Radiation
156
Ipilimumab
144
Lenalidomide
140
Leucovorin
138
Etoposide
134
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
zipalertinib
×
90 days
×
Clear all
NCT07128199
2026-05-05
REZILIENT4
Taiho Oncology, Inc.
Phase 3
Active not recruiting
360 enrolled
NCT05967689
2026-04-03
REZILIENT2
Taiho Oncology, Inc.
Phase 2
Recruiting
220 enrolled
NCT05973773
2026-03-10
REZILIENT3
Taiho Oncology, Inc.
Phase 3
Active not recruiting
285 enrolled